Acta Pharmaceutica Sinica BPharmacology & ToxicologyPeer-reviewed journal article
Engineered flavonoid disrupts mitochondrial AIF/CHCHD4 complex for targeted cancer therapy
Hong-Toan LaiiD, Daniela Dias‐PedrosoiD, Maria Eugénia Marques Da CostaiD, Romain Fernandes, Tran Ngoc Anh Nguyen, Olivia BawaiD, Pierre KhneisseriD, João Gabriel SilvaiD, Yassine Khalij, Michelangelo CampanellaiD, John Griffith JonesiD, Svetlana DokudovskayaiD, Guido KroemeriD, Antonin MarchaisiD, Nathalie GaspariD, Birgit GeoergeriD, Oumar Diane, Liuba MazzantiiD, Tâp Ha‐DuongiD, Guy Lewin, Laurent FerriéiD, Bruno FigadèreiD, Catherine BrenneriD
Abstract
Oncogenic metabolism depends on multifaceted mechanisms, including bidirectional inter-organelle communication between mitochondria and the nucleus, facilitating cellular adaptation at the transcriptomic, proteomic, and metabolomic levels. The mitochondrial protein complex composed of apoptosis-inducing factor (AIF) and coiled-coil-helix-coiled-coil-helix domain-containing protein 4 (CHCHD4) is essential for this mitochondrio-nuclear communication. The AIF/CHCHD4 complex mediates the mitochondrial import of cysteine-enriched nuclear gene-encoded proteins, thereby adapting the mitochondrial proteome to cellular energy demands. We report the discovery of M30-E05, an engineered flavonoid that binds to the NADH pocket of AIF, preventing its dimerization and disrupting the AIF/CHCHD4 complex. Molecular docking and gel electrophoresis analysis of mitochondrial AIF/CHCHD4 substrates expression confirm this mechanism. In cancer cells, M30-E05 reduces the expression of nuclear gene-encoded mitochondrial proteins such as AIF, CHCHD4, COX17, and MICU1. In addition, M30-E05 fragments the mitochondrial network and impairs mitochondrial respiration, causing profound alterations, particularly in lipid and aminoacid metabolism, as revealed by kinetic measurements of oxygen consumption and mass spectrometric metabolomics. Importantly, M30-E05 significantly reduces the viability of a human adult and pediatric osteosarcoma cancer cell panel, including those from patient-derived xenografts (PDX) of osteosarcomas, and induces apoptosis. When orally administered for two weeks to immunodeficient NSG mice, M30-E05 inhibited tumor growth in a subcutaneous PDX xenograft model without apparent toxicity. We anticipate that M30-E05, as a first-in-class metabolic inhibitor, could serve as the lead compound for a new class of targeted antineoplastic agents. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=120 SRC="FIGDIR/small/642976v1_ufig1.gif" ALT="Figure 1"> View larger version (40K): org.highwire.dtl.DTLVardef@1b1add9org.highwire.dtl.DTLVardef@cac7corg.highwire.dtl.DTLVardef@101c9corg.highwire.dtl.DTLVardef@1c6845f_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: human
- assay: proteomics
- assay: metabolomics
- research focus: cancer & tumor microenvironment
- approach: experimental assay
- Citations
- 1
- FWCI
- 2.08
- Field percentile
- top 22%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Combined inhibition of AIF/CHCHD4 interaction and GLS1 to exploit metabolic vulnerabilities in pediatric osteosarcoma
Hong-Toan Lai, Tran Ngoc Anh Nguyen, … Catherine Brenner·bioRxiv·Apr 7, 2026
- CHCHD4 confers metabolic vulnerabilities to tumour cells through its control of the mitochondrial respiratory chain.
L. W. Thomas, J. M. Stephen, … M. Ashcroft·bioRxiv·Jan 7, 2019
- Ophiobolin A Covalently Targets Complex IV Leading to Mitochondrial Metabolic Collapse in Cancer Cells
F. A. Gowans, D. Q. Thach, … D. K. Nomura·bioRxiv·Mar 9, 2023
- Mitochondrial ETF insufficiency drives neoplastic growth by selectively optimizing cancer bioenergetics
David J. Papadopoli, Ranveer Palia, … Ivan Topisirović·eLifePeer-reviewed·May 5, 2026
- Functional plasticity of AIF revealed by dimerization and CHCHD4 interaction states
Olga Soriano, Soraya Hernández-Hatibi, … Patrícia Ferreira·bioRxiv·Sep 1, 2026
- Selective Mitochondrial Respiratory Complex I Subunit Deficiency Causes Tumor Immunogenicity
J. Liang, T. Vitale, … P. Puigserver·bioRxiv·Oct 2, 2023